Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

MOG (35-55) TFA (Alias: Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA, MOG (35-55) (TF...)

Catalog No. TP1091 Copy Product Info
🥰Excellent
MOG (35-55) TFA is a minor component of central nervous system myelin with encephalitogenic activity. It can induce T cell proliferation, activate Th1 cytokine responses, and elicit high levels of IgG antibodies, leading to relapsing-remitting central nervous system disease characterized by extensive plaque-like demyelination. It is commonly used to induce experimental autoimmune encephalomyelitis (EAE) models.

MOG (35-55) TFA

Copy Product Info
🥰Excellent
Catalog No. TP1091
Alias Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA, MOG (35-55) (TFA)

MOG (35-55) TFA is a minor component of central nervous system myelin with encephalitogenic activity. It can induce T cell proliferation, activate Th1 cytokine responses, and elicit high levels of IgG antibodies, leading to relapsing-remitting central nervous system disease characterized by extensive plaque-like demyelination. It is commonly used to induce experimental autoimmune encephalomyelitis (EAE) models.

MOG
(35-55) TFA
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$121InquiryInquiry
5 mg$369InquiryInquiry
10 mg$625InquiryInquiry
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
MOG (35-55) TFA is a minor component of central nervous system myelin with encephalitogenic activity. It can induce T cell proliferation, activate Th1 cytokine responses, and elicit high levels of IgG antibodies, leading to relapsing-remitting central nervous system disease characterized by extensive plaque-like demyelination. It is commonly used to induce experimental autoimmune encephalomyelitis (EAE) models.
Disease Modeling Protocol
Experimental autoimmune encephalomyelitis (EAE) model
  • Modeling Mechanism:

    MOG (35-55) TFA can activate CD4⁺ T cells (Th1 and Th17 subsets), triggering CNS inflammatory infiltration, demyelination, and neurological dysfunction (T cell-mediated in WT mice); GILT⁻/⁻ mice, due to antigen processing defects, cannot process MOG protein into MOG₃₅₋₅₅ epitopes, leading to a shift in the pathogenic mechanism to antibody-mediated—producing pathogenic antibodies that recognize naturally glycosylated MOGs, which bind to MOGs on the surface of oligodendrocytes (OLs), inducing changes in cell morphology and dysfunction, while CNS infiltration is mainly in plasma cells.

  • Related Products:

    MOG (35-55) TFA (TP1091)

  • Modeling Method:

    Experimental Subject:

    Mice: C57BL/6 (WT), GILT⁻/⁻ (C57BL/6 background); female; 6–10 weeks old

    Dosage and Administration Route:

    300 μg MOG₃₅₋₅₅ peptide or 100 μg recombinant rat MOG protein, Emulsified in CFA containing 300 μg Mycobacterium tuberculosis, Subcutaneous injection; 500 ng pertussis toxin, Intraperitoneal injection

    Dosing Frequency and Duration Model:

    Immunisation: 1 dose each on days 0 and 7 (antigen+CFA); 1 dose each on days 0 and 2 (PTX)

  • Validation:

    WT mice showed significant immunopathogenesis with MOG₃₅₋₅₅ (highest score 3.25), while GILT⁻/⁻ mice with rratMOG showed even more severe immunopathogenesis (highest score 4.25); inflammatory infiltration was observed in the CNS tissues (predominantly monocytes in WT, and predominantly CD38⁺CD138⁺ plasma cells in GILT⁻/⁻); serum anti-MOG antibody titers in GILT⁻/⁻ mice were > 1:25600, indicating the possibility of passive transfer of EAE.

*Precautions: All mice were sacrificed 40 days after modeling.

*References:Bergman CM,et,al. A switch in pathogenic mechanism in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in IFN-γ-inducible lysosomal thiol reductase-free mice. J Immunol. 2012 Jun 15;188(12):6001-9.

SynonymsMyelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA, MOG (35-55) (TFA)
Chemical Properties
Molecular Weight2695.97
FormulaC120H178F3N35O31S
Relative Density.no data available
SequenceH-Met-Glu-Val-Gly-Trp-Tyr-Arg-Pro-Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-Lys-OH
Sequence ShortMEVGWYRPPFSRVVHLYRNGK
Storage & Solubility Information
Storagekeep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy MOG (35-55) TFA | purchase MOG (35-55) TFA | MOG (35-55) TFA cost | order MOG (35-55) TFA | MOG (35-55) TFA formula | MOG (35-55) TFA molecular weight